Showing results (1421-1430 of 1,451) with videos related to

Sort By:
Pageof 146
Schizophrenia (Heidelberg, Germany)|October 15, 2025
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiativeZarina R Bilgrami, Eduardo Castro, Carla Agurto, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington, Lu Liu, Amy Braun, et al.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia (Heidelberg, Germany)|April 2, 2025
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia ProgramMichael P Harms, Kang-Ik K Cho, Alan Anticevic, et al.
The American Journal of Psychiatry|October 8, 2025
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve ThemOliver D Howes, Bernard R Bukala, Eric Y H Chen, et al.
Schizophrenia (Heidelberg, Germany)|March 25, 2025
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sampleKelly Allott, Walid Yassin, Luis Alameda, et al.
Pharmacopsychiatry|December 15, 2021
An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine LevelsJose de Leon, Georgios Schoretsanitis, Robert L Smith, et al.
Schizophrenia (Heidelberg, Germany)|June 6, 2025
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measuresDaniel H Mathalon, Spero Nicholas, Brian J Roach, et al.
Schizophrenia Bulletin|March 7, 2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for PsychosisCassandra M J Wannan, Barnaby Nelson, Jean Addington, et al.
Physical Review Letters|March 28, 2025
Observation of the Open-Charm Tetraquark Candidate T_{cs0}^{*}(2870)^{0} in the B^{-}→D^{-}D^{0}K_{S}^{0} DecayR Aaij, A S W Abdelmotteleb, C Abellan Beteta, et al.
Pageof 146